Newbury Pharmaceuticals Secures Generic Approval for Bosutinib tablets
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Newbury Pharmaceuticals via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2025-01-22 09:00:00
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Bosutinib Newbury in Norway as the first country in a Scandinavian registration procedure. Approvals in Sweden and Denmark are expected to follow upon finalized national reviews.
Bosutinib is indicated for the treatment of adult patients with:
- newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).
- CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Bosutinib Newbury is a generic version of Bosulif. The annual value of the Scandinavian market is estimated to be 5,5 MEUR according to DLMI Nordic Pharma Insights.
“The successful approval of Bosutinib Newbury highlights Newbury's capability to offer a comprehensive portfolio within one of our focus areas oncology. Based on this positive progress, we will proceed to launch this product, within respective markets as soon as regulatory exclusivities and patents allow us.” says Mr Lars Minor CEO of Newbury